Royal Bank of Canada set a $147.00 target price on Charles River Laboratories Intl. (NYSE:CRL) in a report issued on Wednesday morning, Marketbeat reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other research firms have also commented on CRL. Raymond James upgraded shares of Charles River Laboratories Intl. from a market perform rating to an outperform rating and set a $140.00 price target for the company in a research report on Thursday, August 23rd. ValuEngine lowered shares of Charles River Laboratories Intl. from a buy rating to a hold rating in a research report on Tuesday, August 28th. SunTrust Banks boosted their price target on shares of Charles River Laboratories Intl. to $135.00 and gave the company a buy rating in a research report on Thursday, August 9th. Robert W. Baird boosted their price target on shares of Charles River Laboratories Intl. from $133.00 to $141.00 and gave the company an outperform rating in a research report on Monday, September 17th. Finally, Bank of America boosted their price target on shares of Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a buy rating in a research report on Monday, July 16th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $130.56.

Shares of CRL traded up $0.35 during mid-day trading on Wednesday, reaching $136.45. 592,301 shares of the stock traded hands, compared to its average volume of 384,159. The firm has a market capitalization of $6.54 billion, a P/E ratio of 25.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48. Charles River Laboratories Intl. has a 1 year low of $96.70 and a 1 year high of $138.89.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating analysts’ consensus estimates of $1.38 by $0.15. The firm had revenue of $585.30 million during the quarter, compared to analyst estimates of $567.58 million. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.81%. The business’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.30 EPS. On average, analysts expect that Charles River Laboratories Intl. will post 5.93 earnings per share for the current year.

In other news, insider David P. Johst sold 23,356 shares of Charles River Laboratories Intl. stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the completion of the sale, the insider now directly owns 219,849 shares of the company’s stock, valued at approximately $29,899,464. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Deborah Turner Kochevar sold 4,066 shares of Charles River Laboratories Intl. stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total transaction of $502,801.56. Following the sale, the director now directly owns 10,190 shares of the company’s stock, valued at $1,260,095.40. The disclosure for this sale can be found here. Insiders have sold a total of 28,671 shares of company stock valued at $3,829,160 over the last ninety days. 2.10% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. NumerixS Investment Technologies Inc bought a new stake in Charles River Laboratories Intl. in the second quarter worth $122,000. CIBC Asset Management Inc bought a new stake in Charles River Laboratories Intl. in the third quarter worth $226,000. Clinton Group Inc. bought a new stake in Charles River Laboratories Intl. in the third quarter worth $241,000. Wsfs Capital Management LLC bought a new stake in Charles River Laboratories Intl. in the second quarter worth $203,000. Finally, CIBC Private Wealth Group LLC bought a new stake in Charles River Laboratories Intl. in the second quarter worth $212,000. 96.93% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Technical Analysis

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.